Company intelligence / Profile preview

Anchiano Therapeutics Ltd.

Cambridge, Massachusetts, USAsec.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Anchiano Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel therapies—primarily a first-in-class gene therapy—for non-muscle invasive bladder cancer. Its lead candidate, inodiftagene vixteplasmid, showed promising complete response rates in early trials and advanced into registrational studies. The company also developed small molecule programs targeting the RAS and β-catenin pathways. In March 2021, Anchiano merged with Chemomab Ltd., after which its independent development activities ceased and some assets were divested or discontinued.[8][9]

Therapeutic areas: OncologyImmunology
Modalities: Gene therapy[6]Small molecules[5]Monoclonal antibodies (limited pipeline evidence)[4]
Industry: Biotech

Drug pipeline

1 asset

inodiftagene

Phase 2

Indications: Non-muscle invasive bladder cancer

Partnerships

Collaboration/license agreement with ADT Pharmaceuticals LLC for pan-RAS and PDE10/β-catenin programs [5].

Beyond the preview

Go deeper on Anchiano Therapeutics Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anchiano Therapeutics Ltd..

Explore the full profile